| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ARHGAP29 |
| Uniprot No | Q52LW3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1261aa |
| 氨基酸序列 | MIAHKQKKTKKKRAWASGQLSTDITTSEMGLKSLSSNSIFDPDYIKELVNDIRKFSHMLLYLKEAIFSDCFKEVIHIRLEELLRVLKSIMNKHQNLNSVDLQNAAEMLTAKVKAVNFTEVNEENKNDLFQEVFSSIETLAFTFGNILTNFLMGDVGNDSLLRLPVSRETKSFENVSVESVDSSSEKGNFSPLELDNVLLKNTDSIELALSYAKTWSKYTKNIVSWVEKKLNLELESTRNMVKLAEATRTNIGIQEFMPLQSLFTNALLNDIESSHLLQQTIAALQANKFVQPLLGRKNEMEKQRKEIKELWKQEQNKMLEAENALKKAKLLCMQRQDEYEKAKSSMFRAEEEHLSSSGGLAKNLNKQLEKKRRLEEEALQKVEEANELYKVCVTNVEERRNDLENTKREILAQLRTLVFQCDLTLKAVTVNLFHMQHLQAASLADSLQSLCDSAKLYDPGQEYSEFVKATNSTEEEKVDGNVNKHLNSSQPSGFGPANSLEDVVRLPDSSNKIEEDRCSNSADITGPSFIRSWTFGMFSDSESTGGSSESRSLDSESISPGDFHRKLPRTPSSGTMSSADDLDEREPPSPSETGPNSLGTFKKTLMSKAALTHKFRKLRSPTKCRDCEGIVVFQGVECEECLLVCHRKCLENLVIICGHQKLPGKIHLFGAEFTQVAKKEPDGIPFILKICASEIENRALCLQGIYRVCGNKIKTEKLCQALENGMHLVDISEFSSHDICDVLKLYLRQLPEPFILFRLYKEFIDLAKEIQHVNEEQETKKNSLEDKKWPNMCIEINRILLKSKDLLRQLPASNFNSLHFLIVHLKRVVDHAEENKMNSKNLGVIFGPSLIRPRPTTAPITISSLAEYSNQARLVEFLITYSQKIFDGSLQPQDVMCSIGVVDQGCFPKPLLSPEERDIERSMKSLFFSSKEDIHTSESESKIFERATSFEESERKQNALGKCDACLSDKAQLLLDQEAESASQKIEDGKTPKPLSLKSDRSTNNVERHTPRTKIRPVSLPVDRLLLASPPNERNGRNMGNVNLDKFCKNPAFEGVNRKDAATTVCSKFNGFDQQTLQKIQDKQYEQNSLTAKTTMIMPSALQEKGVTTSLQISGDHSINATQPSKPYAEPVRSVREASERRSSDSYPLAPVRAPRTLQPQHWTTFYKPHAPIISIRGNEEKPASPSAAVPPGTDHDPHGLVVKSMPDPDKASACPGQATGQPKEDSEELGLPDVNPMCQRPRLKRMQQFEDLEGEIPQFV |
| 预测分子量 | 142 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ARHGAP29重组蛋白的模拟参考文献(信息为示例，非真实文献)：
1. **标题**: *"Recombinant ARHGAP29 protein inhibits RhoA signaling and regulates epithelial cell migration"*
**作者**: Smith J, et al.
**摘要**: 研究报道了重组ARHGAP29蛋白的体外功能，证实其通过水解RhoA-GTP抑制下游信号通路，进而调节上皮细胞的迁移能力，为癌症转移机制提供了新见解。
2. **标题**: *"Expression and purification of functional ARHGAP29 in E. coli for structural analysis"*
**作者**: Zhang L, et al.
**摘要**: 本文描述了一种高效表达和纯化重组ARHGAP29蛋白的方法，通过大肠杆菌系统获得高纯度蛋白，并利用X射线晶体学解析其催化结构域的三维结构。
3. **标题**: *"ARHGAP29 modulates TGF-β-induced cytoskeletal remodeling in fibrosis development"*
**作者**: Lee S, et al.
**摘要**: 研究发现重组ARHGAP29蛋白可干预TGF-β信号通路，通过抑制RhoA/ROCK通路减少肌成纤维细胞活化，提示其在抗纤维化治疗中的潜在应用。
4. **标题**: *"ARHGAP29 deficiency disrupts embryonic neural tube closure via dysregulated actomyosin contractility"*
**作者**: Chen R, et al.
**摘要**: 利用重组ARHGAP29蛋白进行功能挽救实验，揭示了其在胚胎神经管发育中通过调控细胞骨架张力维持组织完整性的关键作用。
(注：以上文献为示例性内容，实际研究中请通过学术数据库检索真实文献。)
ARHGAP29 is a member of the Rho GTPase-activating protein (RhoGAP) family, which plays a critical role in regulating Rho GTPases, particularly RhoA. These proteins function as molecular switches, cycling between active GTP-bound and inactive GDP-bound states to control cytoskeletal dynamics, cell adhesion, migration, and polarity. ARHGAP29 specifically accelerates the hydrolysis of GTP to GDP on RhoA, thereby inactivating it. This activity modulates downstream signaling pathways involved in cellular processes such as stress fiber formation, focal adhesion assembly, and actomyosin contractility. Dysregulation of ARHGAP29 has been implicated in pathological conditions, including cancer metastasis, cardiovascular diseases, and fibrotic disorders, highlighting its importance in maintaining tissue homeostasis.
Recombinant ARHGAP29 protein is engineered for experimental studies to elucidate its molecular mechanisms and interactions. Produced through heterologous expression systems (e.g., bacterial, insect, or mammalian cells), the recombinant protein retains functional domains, such as the RhoGAP catalytic domain and pleckstrin homology (PH) domain, which mediate its localization and activity. Purification techniques like affinity chromatography ensure high specificity and yield. Researchers utilize this protein in vitro to study its binding partners, enzymatic kinetics, and structural features. It also serves as a tool to inhibit RhoA signaling in cellular assays, enabling investigations into ARHGAP29's role in processes like endothelial barrier function, epithelial morphogenesis, or cancer cell invasion.
The development of ARHGAP29 recombinant protein has advanced both basic and translational research. Its applications range from drug discovery targeting RhoA-dependent pathways to understanding developmental biology. Studies using this protein have revealed its context-dependent roles—for example, acting as a tumor suppressor in certain cancers while promoting fibrosis in others. Additionally, ARHGAP29 polymorphisms are linked to susceptibility to cleft palate and vascular anomalies, underscoring its diverse physiological relevance. By providing a controlled, pure protein source, recombinant ARHGAP29 facilitates mechanistic insights and therapeutic exploration in diseases associated with Rho signaling dysregulation.
×
